PARKINSON'S DISEASE NEWS
29th April 2011 - New research
NEW CLINICAL TRIAL OF COGANE FOR PARKINSON'S DISEASE
Cogane, which can be taken orally, readily crosses the blood-brain barrier and has been shown to stimulate the release of GDNF. For more details see the Complete abstract. In theory, GDNF could biochemically increase somebody's ability to produce their own dopamine. However, an animal study showed that this effect would reverse over time. GDNF was the subject of the controversial Amgen trial, which claimed to rid some people of Parkinson's Disease. Cogane has been claimed to reduce the effects of Parkinson's Disease. However, the study was only carried out on animals, who did not actually have Parkinson's Disease. The study did not measure the long term effects, and the full details of the clinical trial have not been made available for analysis.
Studies evaluated Cogane in healthy adults and people with Parkinsonís Disease. Cogane was shown to be safe and generally well tolerated over the 28-day study period. For more information go to Cogane. A new longer clinical trial is being arranged to assess whether Cogane works (whether it can improve symptoms or prevent them from worsening), is safe and well tolerated in people with early-stage Parkinsonís Disease, and to determine how the body deals with Cogane. For more information go to PDTrials. In order to refer to this article on its own click here.
27th April 2011 - New research
INTESTINAL BACTERIA IS HIGHLY PREVALENT IN PARKINSON'S DISEASE
Movement Disorders  26 (5) : 889-892 (Gabrielli M, Bonazzi P, Scarpellini
E, Bendia E, Lauritano EC, Fasano A, Ceravolo MG, Capecci M, Rita Bentivoglio A,
Provinciali L, Tonali PA, Gasbarrini A.)
This can lead to the following symptoms : excess gas, abdominal bloating and distension, abdominal pain, and diarrhea or in some cases chronic constipation. For more information go to Small intestinal bacterial overgrowth. The researchers suggest that the gastrointestinal motility abnormalities that often occur in Parkinson's Disease might explain this association. In order to refer to this article on its own click here.
23rd April 2011 - New book
SWALLOW SAFELY - HOW SWALLOWING PROBLEMS THREATEN THE ELDERLY AND OTHERS
Roya Sayadi, Joel Herskowitz
Publisher's description : "Swallow Safely" is "A Caregiver's Guide to Recognition, Treatment, and Prevention". Relatively few people realize the danger of swallowing problems. They take tens of thousands of lives every year through choking, pneumonia, and malnutrition. "Swallow Safely" seeks to erase this knowledge gap. The book presents in clear, non-technical language with illustrations how swallowing works normally, how things can go wrong, what symptoms to watch out for, and how to get help. The book is written primarily for caregivers of elderly persons and others with medical and neurologic problems such as Parkinson disease, which is commonly associated with swallowing problems. Click here for more details. For the book's web site go to Swallow Safely. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
21st April 2011 - New research
IRON IS ASSOCIATED WITH REDUCED PARKINSON'S DISEASE
Journal of Neurological Science  Apr 15. [Epub ahead of print]
(Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda
T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M)
19th April 2011 - New research
CHANGING FROM L-DOPA TO MELEVODOPA
Medica  102 (2) : 125-132 (Bosco D, Plastino M, Bosco F, Fava A, Rotondo
In the present study, when people were switched from Sinemet to Melevodopa people improved regarding their "On-time". The benefit was greater in people with "delayed-on", and especially in those with both "delayed-on" and "wearing-off". Most patients showed a significant improvement in PDQ-39 total score (a standard Parkinson's Disease symptom questionnaire). The authors conclude that Melevodopa is an effective agent for improving motor performance and quality-of-life in Parkinson's Disease with "delayed-on" and with "wearing-off". In order to refer to this article on its own click here.
16th April 2011 - New research
THE CONSENSUS ON DBS FOR PARKINSON'S DISEASE
Archives of Neurology  68 (2) : 165
(Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak
FB, Okun MS, Foote KD, Krack P, Pahwa R, Henderson JM, Hariz MI, Bakay RA, Rezai
A, Marks WJ Jr, Moro E, Vitek JL, Weaver FM, Gross RE, DeLong MR.)
The following recommendations were agreed on by all members : (1) Patients with Parkinson's Disease without significant active cognitive or psychiatric problems who have medically intractable motor fluctuations, intractable tremor, or intolerance of medication adverse effects are good candidates for DBS. (2) DBS surgery is best performed by an experienced neurosurgeon with expertise in stereotactic neurosurgery who is working as part of a inter-professional team. (3) Surgical complication rates are extremely variable, with infection being the most commonly reported complication of DBS. (4) DBS programming is best accomplished by a highly trained clinician and can take 3 to 6 months to obtain optimal results. (5) DBS improves L-dopa responsive symptoms, dyskinesia, and tremor. Benefits seem to be long-lasting in many motor domains. (6) Subthalamic nuclei DBS may be complicated by increased depression, apathy, impulsivity, worsened verbal fluency, and executive dysfunction in some patients. (7) Both globus pallidus pars interna and subthalamic nuclei DBS have been shown to be effective in addressing the motor symptoms of Parkinson's Disease. (8) Ablative therapy is still an effective alternative and should be considered in a select group of appropriate patients. In order to refer to this article on its own click here.
14th April 2011 - New research
DO BOTH TWINS GET PARKINSON'S DISEASE
Neurobiology of Aging  Apr 9. [Epub ahead of
print] (Wirdefeldt K, Gatz M, Reynolds CA, Prescott CA, Pedersen NL.)
5th April 2011 - New research
JAPANESE AND CHINESE TEA REDUCE THE RISK OF PARKINSON'S DISEASE
Parkinsonism Related Disorders  Mar 30 [Epub
ahead of print] (Tanaka K, Miyake Y, Fukushima W, Sasaki S, Kiyohara C, Tsuboi
Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M)